C-C motif chemokine receptor 3Genealiases: C C CKR3 · CC-CKR-3 · CD193 · CKR 3 · CKR3 · CMKBR3
Q-omics provides the consensus-scored CCR3 profile across patient tissues and cancer cell-line models. CCR3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CCR3 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, CCR3 RNA expression shows 13,299 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, BLCA, and LSCC as cancer lineages where CCR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCR3 survival associations across molecular data types. CCR3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCR3 RNA expression–survival associations across cancer types. High CCR3 expression shows unfavorable associations in KICH, STAD, KIRP, HNSC and LIHC, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for CCR3 RNA expression.
This table summarizes CCR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCR3 shows higher tumor expression in BLCA, THCA, LUAD, BRCA, KIRC and LIHC. The BLCA box plot shows higher CCR3 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with CCR3 in patient tissues and cancer cell lines. In patient samples, CCR3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
